- Home
- PLBY vs CGEN Comparison
PLBY vs CGEN Comparison
Compare PLBY & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBY
- CGEN
- Stock Information
- Founded
- PLBY 1953
- CGEN 1993
- Country
- PLBY United States
- CGEN Israel
- Employees
- PLBY N/A
- CGEN N/A
- Industry
- PLBY Recreational Games/Products/Toys
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLBY Consumer Discretionary
- CGEN Health Care
- Exchange
- PLBY Nasdaq
- CGEN Nasdaq
- Market Cap
- PLBY 113.4M
- CGEN 117.8M
- IPO Year
- PLBY N/A
- CGEN 2000
- Fundamental
- Price
- PLBY $1.56
- CGEN $1.51
- Analyst Decision
- PLBY Hold
- CGEN Strong Buy
- Analyst Count
- PLBY 1
- CGEN 1
- Target Price
- PLBY $0.70
- CGEN $4.00
- AVG Volume (30 Days)
- PLBY 603.4K
- CGEN 216.5K
- Earning Date
- PLBY 05-15-2025
- CGEN 05-19-2025
- Dividend Yield
- PLBY N/A
- CGEN N/A
- EPS Growth
- PLBY N/A
- CGEN N/A
- EPS
- PLBY N/A
- CGEN N/A
- Revenue
- PLBY $116,691,000.00
- CGEN $27,589,000.00
- Revenue This Year
- PLBY $5.30
- CGEN $11.81
- Revenue Next Year
- PLBY $2.08
- CGEN $28.37
- P/E Ratio
- PLBY N/A
- CGEN N/A
- Revenue Growth
- PLBY N/A
- CGEN N/A
- 52 Week Low
- PLBY $0.52
- CGEN $1.13
- 52 Week High
- PLBY $2.44
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PLBY 65.06
- CGEN 56.16
- Support Level
- PLBY $1.53
- CGEN $1.38
- Resistance Level
- PLBY $1.65
- CGEN $1.56
- Average True Range (ATR)
- PLBY 0.13
- CGEN 0.08
- MACD
- PLBY 0.02
- CGEN 0.02
- Stochastic Oscillator
- PLBY 81.69
- CGEN 77.74
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.